Smith Group Asset Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Smith Group Asset Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,372	Closed	-$63K	–	382
2020 Q1	$63K	Hold	1,372	–	–	﹤0.01%	235
2019 Q4	$82K	Hold	1,372	–	–	﹤0.01%	248
2019 Q3	$78K	Hold	1,372	–	–	﹤0.01%	250
2019 Q2	$76K	Hold	1,372	–	–	﹤0.01%	254
2019 Q1	$69K	Sell	1,372 -80	-6%	-$3.56K	﹤0.01%	282
2018 Q4	$59K	Hold	1,452	–	–	﹤0.01%	294
2018 Q3	$101K	Hold	1,452	–	–	﹤0.01%	274
2018 Q2	$110K	Sell	1,452 -1,930	-57%	-$121K	﹤0.01%	279
2018 Q1	$178K	Sell	3,382 -118	-3%	-$6.86K	0.01%	262
2017 Q4	$187K	Buy	+3,500	New	+$195K	0.01%	260

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Smith Group Asset Management's EGRX Position: Q2 2020 in Review

Smith Group Asset Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2020, closing a stake of 1,372 shares — an estimated $63K sold.

Smith Group Asset Management first reported a position in EGRX in Q4 2017 and held it in 10 quarters. The position peaked at $187K in Q4 2017. 164 funds tracked by Wall St. Rank hold EGRX as of Q2 2020.

Smith Group Asset Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Smith Group Asset Management sold 1,372 Eagle Pharmaceuticals, Inc. shares in Q2 2020, an estimated $63K.
Smith Group Asset Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 10 quarters.
Smith Group Asset Management's Eagle Pharmaceuticals, Inc. position peaked at $187K in Q4 2017.
164 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2020.

Based on Smith Group Asset Management's 13F filing for Q2 2020, filed 6 Aug 2020.